


## Pardoprinox

<b>Cat. No.:</b>	HY-14958
<b>CAS No.:</b>	269718-84-5
<b>Molecular Formula:</b>	C <sub>12</sub> H <sub>15</sub> N <sub>3</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	233.27
<b>Target:</b>	5-HT Receptor; Adrenergic Receptor; Dopamine Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Pardoprinox (SLV-308) is a partial dopamine D <sub>2</sub> and D <sub>3</sub> receptor partial agonist and a serotonin 5-HT <sub>1A</sub> receptor agonist, with pEC <sub>50</sub> s of 8, 9.2, and 6.3, respectively <sup>[1]</sup> .		
<b>IC<sub>50</sub> &amp; Target</b>	5-HT <sub>1A</sub> Receptor 6.3 (pEC <sub>50</sub> )	D <sub>2</sub> Receptor 8 (pEC <sub>50</sub> )	D <sub>3</sub> Receptor 9.2 (pEC <sub>50</sub> )
<b>In Vitro</b>	Pardoprinox (SLV-308) acts as a potent but partial D <sub>2</sub> receptor agonist (pEC <sub>50</sub> =8.0 and pA <sub>2</sub> =8.4) with an efficacy of 50% on forskolin stimulated cAMP accumulation. At human recombinant dopamine D <sub>3</sub> receptors, Pardoprinox acts as a partial agonist in the induction of [(35)S]GTPgammaS binding (intrinsic activity of 67%; pEC <sub>50</sub> =9.2) and antagonized the dopamine induction of [(35)S]GTPgammaS binding (pA <sub>2</sub> =9.0). Pardoprinox acts as a full 5-HT <sub>1A</sub> receptor agonist on forskolin induced cAMP accumulation at cloned human 5-HT <sub>1A</sub> receptors but with low potency (pEC <sub>50</sub> =6.3) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

### REFERENCES

- [1]. Glennon JC, et al. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D<sub>2</sub> and D<sub>3</sub> receptor agonist and serotonin 5-HT<sub>1A</sub> receptor agonist. *Synapse*. 2006 Dec 15;60(8):599-608.
- [2]. Bronzova J, et al. Double-blind study of pardoprinox, a new partial dopamine agonist, in early Parkinson's disease. *Mov Disord*. 2010 Apr 30;25(6):738-46.
- [3]. Bétry C, et al. In vivo effects of pardoprinox (SLV308), a partial D<sub>2</sub>/D<sub>3</sub> receptor and 5-HT<sub>1A</sub> receptor agonist, on rat dopamine and serotonin neuronal activity. *Synapse*. 2011 Oct;65(10):1042-51.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA